Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2
diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly
high-risk group with about 50% who will develop T2DM within 5 years after the delivery.
Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with
similarly elevated glucose levels. Early intervention after the index pregnancy is therefore
crucial to prevent T2DM. With the SERENA project, we aim therefore to reduce the risk to
develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of
GDM and glucose intolerance in early postpartum.
Phase:
Phase 3
Details
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborators:
AZ Delta Centre Hospitalier Mouscron Centre Hospitalier Universitaire de Liege Erasme University Hospital General Hospital Groeninge Jessa Hospital Onze Lieve Vrouw Hospital Universitair Ziekenhuis Brussel UZA Vitaz Ziekenhuis Netwerk Antwerpen (ZNA)